A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MEDI0382 in Obese Subjects with a History of Type 2 Diabetes Mellitus
Phase of Trial: Phase I/II
Latest Information Update: 17 Jul 2017
At a glance
- Drugs MEDI 0382 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors MedImmune
- 09 Mar 2017 Status changed to completed.
- 18 Oct 2016 Planned End Date changed from 1 Apr 2017 to 1 Mar 2017.
- 11 Oct 2016 Planned number of patients changed from 75 to 107.